# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Needham analyst Ami Fadia reiterates Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Buy and maintains $205 price target.
Cantor Fitzgerald analyst Charles Duncan reiterates Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Overweight and maintains $140 ...
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced that the Company, along with its partners, will present five abstracts a...
The notes will be general unsecured obligations of the Issuer and will accrue interest payable semiannually in arrears on March...
Jazz Pharmaceuticals, together with its consolidated subsidiaries, expects to use a portion of the net proceeds to prepay up to...
Jazz Pharmaceuticals and Hikma Pharmaceuticals will face trial over allegations of delaying a generic version of Xyrem, causing...